Suzhou Zhide Cloud Chuang Intelligent Co., Ltd.

The company and all members of the board of directors guarantee that the information disclosed is true, accurate, and complete, without false records, misleading statements, or significant omissions.

Lepu (Beijing) Medical Equipment Co., Ltd. (hereinafter referred to as the "Company") learned today that its subsidiary, Sichuan Xingtai Pule Medical Technology Co., Ltd., has obtained registration approval from the National Medical Products Administration (NMPA) for its self-developed sodium hyaluronate solution for injection, with registration certificate number: National Medical Equipment Administration (NMPA) 20253131324.

一、 PRODUCT INFORMATION

二、 Impact on the company

Sodium hyaluronate solution for injection belongs to the category of water light needle products. Water light needle is a "mesodermal therapy" that effectively solves the problem of difficult transdermal absorption of skincare products by precisely injecting nutrients into the superficial or middle layers of the dermis. The main raw material of Shuguang needle is hyaluronic acid (scientific name hyaluronic acid), which is an extracellular matrix component widely distributed in tissues such as dermis, lens, and articular cartilage in humans and animals;It is injected into facial tissues as a tissue filler, which can provide support for filling, and due to its material properties, it can achieve the goals of filling facial depressions, moisturizing the skin, etc. The successful approval of sodium hyaluronate solution for injection further enriches the company's product matrix in the field of dermatology, and will leverage synergies with existing products to meet increasingly diverse market demands, which will help the company expand its business in the consumer healthcare sector and is expected to have a positive impact on the company's development.

三、 Risk statement

The specific sales situation of a new product during the promotion process may be affected by factors including but not limited to clinical promotion, channel development, changes in competitive landscape, macro policies, etc. The impact of this product on the company's future performance is uncertain. Investors are advised to pay attention to investment risks.

This is to announce.

Lepu (Beijing) Medical Equipment Co., Ltd

board of directors

二〇二五年七月十一日